{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:27:30Z","timestamp":1786746450417,"version":"build-2736575974"},"reference-count":44,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s417180","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:50:05Z","timestamp":1692759005000},"page":"2073-2084","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia"],"prefix":"10.2147","volume":"Volume 17","author":[{"given":"Xiaoxiao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":true,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Kinkead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasiulla","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fpubh.2017.00335","volume":"5","author":"Jaul","year":"2017","journal-title":"Front Public Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.5888\/pcd10.120203","volume":"10","author":"Ward","year":"2013","journal-title":"Prev Chronic Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1517\/14740338.2013.827660","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref6","unstructured":"Janssen Biotech, Inc.. IMBRUVICA (Ibrutinib) Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2022."},{"key":"ref7","unstructured":"AstraZeneca Pharmaceuticals LP. CALQUENCE (Acalabrutinib) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01054-w","volume":"14","author":"Patel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/NEJMc2005943","volume":"383","author":"Ahn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/s1470-2045(16)30212-1","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"key":"ref17","unstructured":"AstraZeneca. Calquence approved in the US for adult patients with chronic lymphocytic leukaemia. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html#!. Accessed September 15, 2022."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sharman JP, Egyed M, Wojciech J, et al. Acalabrutinib \u00b1 obinutuzumab versus obinutuzumab + chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: five-year follow-up of ELEVATE-TN. In: 2022 American Society of Clinical Oncology Annual Meeting; Chicago, IL, US; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.7539"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1080\/03007995.2018.1477747","volume":"34","author":"Forbes","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"ref25","unstructured":"Janssen Biotech. IMBRUVICA (Ibrutinib) Specialty Pharmacies and Distributors. Janssen Biotech; 2021."},{"key":"ref26","unstructured":"AstraZeneca. CALQUENCE (Acalabrutinib) Distribution Card. AstraZeneca; 2022."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S1470-2045(21)00455-1","volume":"22","author":"Davids","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2021-148155","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"ref31","first-page":"17","volume":"2017","author":"Pednekar","year":"2017","journal-title":"Value Outcomes Spotlight"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.6004\/jadpro.2021.12.1.2","volume":"12","author":"Garner","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2022.2045597","volume":"63","author":"Collins","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.18553\/jmcp.2012.18.7.527","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","volume":"38","author":"Reginster","year":"2006","journal-title":"Bone"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e56813","DOI":"10.1371\/journal.pone.0056813","volume":"8","author":"Santoleri","year":"2013","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.amjmed.2019.12.021","volume":"133","author":"Gillespie","year":"2020","journal-title":"Am J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12875-019-1019-3","volume":"20","author":"Fernandez-Lazaro","year":"2019","journal-title":"BMC Fam Pract"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","volume":"40","author":"DiMatteo","year":"2002","journal-title":"Med Care"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e016982","DOI":"10.1136\/bmjopen-2017-016982","volume":"8","author":"Cutler","year":"2018","journal-title":"BMJ Open"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/RMHP.S19801","volume":"7","author":"Iuga","year":"2014","journal-title":"Risk Manag Healthc Policy"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Huang Q, Emond B, Lafeuille MH, et al. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. In: The International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2020.","DOI":"10.1080\/03007995.2020.1835851"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e959","DOI":"10.1016\/j.clml.2022.07.004","volume":"22","author":"Narezkina","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1002\/cam4.2559","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92212","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:50:08Z","timestamp":1692759008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/real-world-comparison-of-first-line-treatment-adherence-between-single-peer-reviewed-fulltext-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2147\/ppa.s417180","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}